KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Emergent BioSolutions (EBS) over the last 17 years, with Q3 2025 value amounting to $4.8 million.

  • Emergent BioSolutions' Share-based Compensation rose 10869.57% to $4.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.2 million, marking a year-over-year decrease of 1412.43%. This contributed to the annual value of $18.0 million for FY2024, which is 2207.79% down from last year.
  • As of Q3 2025, Emergent BioSolutions' Share-based Compensation stood at $4.8 million, which was up 10869.57% from $4.6 million recorded in Q2 2025.
  • In the past 5 years, Emergent BioSolutions' Share-based Compensation ranged from a high of $12.3 million in Q2 2022 and a low of $1.5 million during Q1 2025
  • In the last 5 years, Emergent BioSolutions' Share-based Compensation had a median value of $6.8 million in 2023 and averaged $7.3 million.
  • Data for Emergent BioSolutions' Share-based Compensation shows a peak YoY increase of 10869.57% (in 2025) and a maximum YoY decrease of 7457.63% (in 2025) over the last 5 years.
  • Emergent BioSolutions' Share-based Compensation (Quarter) stood at $10.1 million in 2021, then rose by 15.84% to $11.7 million in 2022, then crashed by 65.81% to $4.0 million in 2023, then rose by 7.5% to $4.3 million in 2024, then increased by 11.63% to $4.8 million in 2025.
  • Its Share-based Compensation stands at $4.8 million for Q3 2025, versus $4.6 million for Q2 2025 and $1.5 million for Q1 2025.